The American people deserve the truth. FDA, do you remember Covaxin? The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop, while you were fast-tracking mRNA boosters based on trials conducted on just 8 mice? You urged the company to seek approval through a U.S. BLA trial, and they did—spending over $100 million on a massive Phase 3 trial that yielded top-line data showing broad protection against all variants of concern. Yet, despite this, you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why? Because just months after those results were published, you changed the rules to block any vaccine built on the original virus. This effectively killed the market for traditional vaccines based on the whole coronavirus. Meanwhile, you rolled out the next set of mRNA boosters, designed to mimic just a tiny piece of the spike protein on a virus that’s famously studied for its high mutation rates. It’s been four long years, and you still haven’t approved any competitor vaccines. The government collects royalties from mRNA sales, with companies like Moderna paying over $400 million in a single year. But those profits wouldn’t roll in from a traditional vaccine sale, would they? How has this financial entanglement influenced your decision-making during the pandemic? Your job is to serve the public—to prioritize science and protect the American people. But you’ve failed in that duty. Instead, you’ve used taxpayer dollars to accelerate only the development of “vaccines” that you own patents on, blocking all competitor vaccines for over four years. Do you really think the American people will trust that this next round of mRNA boosters will finally work, after six previous rounds failed to deliver? Your actions have severely damaged your credibility. Government entities should never receive kickbacks from the sales of drugs they’re responsible for approving. This is an egregious conflict of interest, and we’re living with the consequences. The amount of blood on your hands is staggering. Next-generation vaccines that have been proven to stop transmission are approved overseas, yet Americans have no choice but to take this mRNA snake oil. This is the biggest scam our country has ever seen. It’s time for real journalism to uncover the truth. There must be accountability, and the American people deserve to know who the main perpetrators are. Rest in peace to all those lost in this pandemic due to this corruption.

$OCGN one approval validates the platform’s road map, it no longer starts from zero. FDA will have already seen the delivery method, safety profile, manufacturing package, endpoint logic, and clinical design. That creates a regulatory blueprint for the many follow up drugs to come that are built on the same modifier gene therapy platform. This company is going to have back to back to back BLA’s for many years to come. 🍻

$OCGN OCU400 broad RP analysis, realistic revenue projections, and a bonus market cap/share price timeline. Most won’t realize how conservative this framework actually is. 🍻

#OCUGEN Here's the Noble vid from yesterday with @drsmusunuri. Q3 looks to be a busy quarter with OCU410ST interm analysis to see if any changes need to be made to the trial, start of the rolling BLA for OCU400 and the start of the OCU410 "Global trial"💪 youtu.be/HoPzsC2Srxg?si=V80D…

RT @Ocugen: Early #OCU410ST results show: ✓ 54% reduction in atrophic lesion growth ✓ 100% of treated eyes stabilized or improved ✓ 6 lett…

$OCGN I get comments questioning price and people’s ability to pay because they don’t understand the why’s, who’s and where’s of drug pricing. Insurance and payers don’t cover gene therapy because they’re generous, they cover it because the math makes sense. $1.3 million sounds like a lot, but blindness is not just an eye problem. It becomes a lifelong cost burden. Doctors, specialists, disability, lost income, caregivers, falls, depression, assisted living, benefits, lost productivity, and decades of medical and social costs all tied to vision loss. When a one time gene therapy like OCU400 can stop someone from going blind, payers are not just paying for a drug. They are paying to avoid the lifetime burden blindness creates. That’s why these treatments look expensive upfront but still make financial sense. Pay once or keep paying for decades. This is why approved gene therapies in rare retinal diseases get covered. The burden of blindness is massive, and stopping it is worth billions.🍻

$OCGN Here’s the conservative math for OCU400, 50% target market, modestly low market penetration. Ocu400 with “broad RP indication” as a gene agnostic therapy for retinitis pigmentosa: Total amount of people with broad RP(51% ) in USA and EU: 191,250 people Total USA and EU market for Broad RP at $1,350,000 per patient= $258,187,500,000 USD Total conservative market to catch yearly: 1.5% Total yearly Revenue for broad RP in USA/EU Markets = $3,872,812,500 5 year revenue projected: $19,364,062,500 USD Reasonable market cap valuation for a company with a drug bringing in these numbers = $40b on the bearish side $80b on the bullish side. 🍻

RT @OcugenPE: 100,000 people with #Stargardtdisease have no FDA approved treatment. #OCU410ST aims to slow or stop disease progression, wi…

$OCGN Lets go! 😎

$OCGN Hello fam, I want to show you a real example of what happens when biotech speculation turns into reality. The chart below is Celcuity, ticker CELC, over a little more than a year. CELC is a strong comparison to Ocugen in terms of market setup. Pre revenue biotech ignored asset Phase 3 derisking event regulatory filing path huge commercial story = violent rerate. CELC had its major move after the VIKTORIA 1 Phase 3 trial showed gedatolisib produced a 76% reduction in risk of progression or death in the triplet arm and a 67% reduction in the doublet arm versus fulvestrant. After that, the story moved from clinical speculation into NDA submission and FDA review territory. That is what the market does in biotech. It waits. It doubts. It discounts. It suppresses. Then pivotal data hits, the filing path becomes real, and the entire valuation framework changes almost overnight. CELC went from being valued like a risky clinical biotech to being valued like a near commercial oncology company once the data proved the drug worked. Ocugen will go from being valued like a beaten down speculative microcap to being valued like a near commercial gene therapy platform as soon as OCU400 data proves the drug works. There is one exception though, and it is pretty massive. Ocugen has something CELC does not have in the same way: platform stacking. CELC is largely a gedatolisib story. Ocugen has OCU400 as the first major validation point, then OCU410ST behind it, then OCU410 for GA, which both have already shown statistical superiority. OCU400’s pivotal win won’t just cause the market to price in the one drug. It would force the market to reprice the entire modifier gene therapy platform. One product moves toward approval. The platform gets validated. The follow on programs become impossible to discount. Our commercial story becomes reality. 🍻 🐂

$OCGN Institutional ownership is rising fast, and this is before the 2026 Russell reconstitution cycle even hits. Russell finalizes after market close June 26, with the newly reconstituted indexes live June 29. Ocugen has the cash now, and they’re have 3 BLA filings over the next 2 years. Where this stock is going is obvious to me. The whole reason I’m here is to bring retail awareness to what I believe will become the next big pharma before the market recognizes the value. Good news, and lots of it, comes next. When this starts getting crazy, it won’t move in a nice straight line. We’ll stair step up. There will be stop loss raids after jumps, emotional decisions, and regret. If you’ve been here with me on this journey, remember the big picture. Know what you own. Have a plan in place. Let that plan dictate future decisions, not volatility, fear, or big money shake outs and stop losses. We’re approaching the moment where speculation meets reality. Js 🍻

$OCGN #OCUGEN Retail investors get scared and sell, institutional investors are buying it out right under us. Get smart guys! OCGN - Ocugen, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM) share.google/HEALRk6QiyJWCiz…

RT @Ocugen: Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage pr…

“Fatal Hour” lyric video. youtube.com/playlist?list=PL…

One might first see all this pressure to force Marty Makary out of power and think, why would BP want Marty out if he’s the one making it easier for drugs to get approved? Then you start realizing something deeper. That all these hoops, hurdles, delays, and red tape that everyone complains about are the same barriers that make it nearly impossible for smaller companies to navigate alone. You start to wonder if these absurdities are really just overlooked flaws, or if they purposely became part of the design. Then you start noticing that Big Pharma is thriving in a broken system where small companies take all the scientific risk for innovation, spending years bleeding through cash and fighting through constantly changing regulatory uncertainty, only to end up getting forced into partnerships and undervalued buyouts once the data finally proves value. Then a question dawns on you, why would BP take all the early R&D risks themselves when the system allows them to wait, watch and then buy innovations at a great discount off the companies who were courageous enough to attempt to survive their gauntlet? Marty’s FDA changes to the system is a massive direct threat to the most powerful companies in the world. The fact that BP hasn’t already kicked Marty out of power is impressive imo.

$OCGN is perfectly set up for the future. Big news ahead. on.soundcloud.com/OWBodjidGY…

$OCGN Hedging likely slows after today/early tomorrow. What looks bearish is really just positioning after a very bullish bet. Like always, the bearishness here is a fugazi. Capitalize if you can. Times like these are numbered, and there’s very little left to hold us back. 🍻

$ocgn Tutes and funds just bought a long position in Ocugen for $100 million dollars. Big money bets like that hardly ever come without a hedge to protect themselves. What are the odds we saw the hedge today? Imo close to 100%.

RT @drsmusunuri: Encouraging to see continued progress across our pipeline and operations this quarter. With key milestones achieved and a…

$OCGN call said multiple BD(business development deals) term sheets are being looked at. Aka the blueprints for multiple Ex. US partnerships for multiple drugs are mapped out and being looked over. One better be positioned before those PR’s imo. Next couple quarters could very well be the most important and exciting ones to date. 🍻